• Publications
  • Influence
Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants
This study demonstrated that distinct patterns of active behaviors are produced by antidepressants that selectively inhibit norepinephrine (NE) or serotonin (5-HT) uptake in the rat forced swimming test (FST), and showed that SSRIs are not false negatives in the FST.
Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.
Duloxetine, 60 mg/day, is a well-tolerated and effective treatment for MDD that reduces painful physical symptoms and is suggested to be a first-line treatment for patients with MDD and associated painfulPhysical symptoms.
A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Duloxetine was an effective and safe treatment for many of the symptoms associated with fibromyalgia in subjects with or without major depressive disorder, particularly for women, who had significant improvement across most outcome measures.
Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression.
The results indicated that low doses of desipramine and fluoxetine produced different behavioral patterns in the FST, but only after chronic administration, which strengthens the validity of the F ST as a behavioral screen for antidepressant drugs with features similar to an animal model of depression.
Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test
Depletion of serotonin prevented the behavioral effects of the selective serotonin reuptake inhibitor fluoxetine in the rat FST, and depletion of serotonin had no impact on the behavior effects induced by the selective norepinephrine reptake inhibitor, desipramine.
Duloxetine in the Treatment of Depression: A Double-Blind Placebo-Controlled Comparison With Paroxetine
Duloxetine therapy was efficacious for emotional and physical symptoms of depression, with a selective serotonin reuptake inhibitor-like profile of side effects.